SynthesisPloS one2014
The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- No association between HMGB1 polymorphisms and cancer risk: evidence from a meta-analysis.Bioscience reports · 2018Pooled it
- HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review.Oncotarget · 2016Pooled it
- Mechanism of action of HMGB1 in urologic malignancies.Frontiers in oncology · 2025Review
- Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment.Frontiers in oncology · 2025Review
- Review
- Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival.Genome medicine · 2022Article
- Long non-coding RNA DCST1-AS1/hsa-miR-582-5p/HMGB1 axis regulates colorectal cancer progression.Bioengineered · 2022Article
- Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implications.Frontiers in pharmacology · 2022Article
- Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer.Frontiers in molecular biosciences · 2022Article
- Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis.Frontiers in genetics · 2021Article
- Danger signals in liver injury and restoration of homeostasis.Journal of hepatology · 2020Review
- A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury.Journal of cellular and molecular medicine · 2020Article
- High Mobility Group Box 1 in Human Cancer.Cells · 2020Review
- High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.Hepatology (Baltimore, Md.) · 2018Article
- HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition.OncoTargets and therapy · 2017Article
- The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.Oncotarget · 2016Article
- NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?Journal of immunology research · 2016Review
- Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study.Cancer cell international · 2016Article
- The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the fifth most common cancer, and it is the second most common cancer-related mortality globally. The prognostic value of high mobility group box 1 (HMGB1) remains controversial. The purpose of this study is to conduct a meta-analysis and literature review to evaluate the association of HMGB1 expression with the prognosis of patients with HCC.
methodsA detailed literature search was made in Medline, Google Scholar and others for related research publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data were performed, Hazard Ratio (HR) and mean difference with corresponding confidence intervals (CIs) were calculated and summarized respectively.
results10 relevant articles were included for this meta-analysis study. HMGB1 mRNA levels in HCC were significantly higher than those in normal (p<0.00001) and para-tumor tissues (p = 0.002) respectively. The protein levels of HMGB1 in HCC were significantly higher than those in para-tumor tissues (p = 0.005). Two studies reported the serum HMGB1 levels in patients with HCC of TNM stages, and indicating significantly different between stage I and II, stage II and III, as well as stage III and IV (two studies showed p<0.01 and p<0.001 respectively). The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20-1.44, Z = 5.82, p<0.0001. Two additional studies showed that there were higher serum HMGB1 levels in patients with chronic hepatitis than those in healthy people (p<0.05).
conclusionsThe results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively. Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.